Loading company…
Daejeon AI drug discovery company whose DeepMatcher platform generates drug candidates for pharmaceutical and research clients.
Syntekabio, Inc. provides AI-driven drug discovery through its DeepMatcher AI Drug Platform, which generates drug candidates for over 100 disease targets, along with Sm-ARS, NEO-ARS and Ab-ARS solutions. Founded in 2009 and headquartered in Daejeon, South Korea, with Jongsun Jung as CEO, it raised KRW 19.2 billion in an IPO on December 17, 2019, and has completed four deals. Its 2024 revenue was KRW 88,692.2 mn, sold mostly under a SaaS model.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in